David Anderson
Executive Director Aclaris Therapeutics
David has been working in drug discovery and development for more than 25 years and has advanced numerous compounds from project initiation to clinical development for immunology and CNS indications including onfasprodil, plazinemdor, lepzacitinib and modzatinib.
Seminars
Covalent development generates complex kinetic and selectivity data that are often difficult to reconcile across assays and systems. This workshop will focus on how kinact/KI, target engagement and selectivity readouts can be integrated to build translational readiness, supporting clearer alignment between discovery data, PK/PD strategy and downstream development planning.
This session will address:
• Assessing how kinetic, selectivity and target engagement data can be integrated across biochemical and cellular systems to build a consistent view of covalent behavior
• Comparing approaches to generating and contextualizing kinact/KI measurements, including their applicability and limitations across enzyme and non‑enzyme targets
• Linking kinetic and selectivity profiles with early safety and PK/PD considerations to support translational planning and downstream development strategy
